MX2015010296A - Tratamiento de formas progresivas de esclerosis multiple con laquinimod. - Google Patents
Tratamiento de formas progresivas de esclerosis multiple con laquinimod.Info
- Publication number
- MX2015010296A MX2015010296A MX2015010296A MX2015010296A MX2015010296A MX 2015010296 A MX2015010296 A MX 2015010296A MX 2015010296 A MX2015010296 A MX 2015010296A MX 2015010296 A MX2015010296 A MX 2015010296A MX 2015010296 A MX2015010296 A MX 2015010296A
- Authority
- MX
- Mexico
- Prior art keywords
- laquinimod
- multiple sclerosis
- human subject
- treating
- treatment
- Prior art date
Links
- GKWPCEFFIHSJOE-UHFFFAOYSA-N laquinimod Chemical compound OC=1C2=C(Cl)C=CC=C2N(C)C(=O)C=1C(=O)N(CC)C1=CC=CC=C1 GKWPCEFFIHSJOE-UHFFFAOYSA-N 0.000 title abstract 4
- 229960004577 laquinimod Drugs 0.000 title abstract 4
- 201000006417 multiple sclerosis Diseases 0.000 title abstract 4
- 230000000750 progressive effect Effects 0.000 abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Medicinal Preparation (AREA)
- Quinoline Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361765394P | 2013-02-15 | 2013-02-15 | |
| US201361911106P | 2013-12-03 | 2013-12-03 | |
| PCT/US2014/016278 WO2014127139A1 (en) | 2013-02-15 | 2014-02-13 | Treatment of multiple sclerosis with laquinimod |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2015010296A true MX2015010296A (es) | 2016-05-05 |
Family
ID=51351655
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2015010296A MX2015010296A (es) | 2013-02-15 | 2014-02-13 | Tratamiento de formas progresivas de esclerosis multiple con laquinimod. |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US20140235670A1 (enExample) |
| EP (1) | EP2956137A4 (enExample) |
| JP (1) | JP2016510343A (enExample) |
| KR (1) | KR20150119227A (enExample) |
| CN (1) | CN105163737A (enExample) |
| AU (1) | AU2014216199A1 (enExample) |
| BR (1) | BR112015019564A2 (enExample) |
| CA (1) | CA2900503A1 (enExample) |
| CL (1) | CL2015002181A1 (enExample) |
| EA (1) | EA201591507A1 (enExample) |
| HK (2) | HK1218254A1 (enExample) |
| IL (1) | IL240014A0 (enExample) |
| MX (1) | MX2015010296A (enExample) |
| PE (1) | PE20151526A1 (enExample) |
| SG (1) | SG11201505818WA (enExample) |
| TW (1) | TW201442709A (enExample) |
| UY (1) | UY35328A (enExample) |
| WO (1) | WO2014127139A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR089862A1 (es) | 2012-02-03 | 2014-09-24 | Teva Pharma | USO DE LAQUINIMOD PARA EL TRATAMIENTO DE PACIENTES CON ENFERMEDAD DE CROHN EN QUIENES FRACASO UNA TERAPIA ANTI-FACTOR DE NECROSIS TUMORAL a (ANTI-TNFa) DE PRIMERA LINEA |
| AR090885A1 (es) * | 2012-05-02 | 2014-12-10 | Teva Pharma | Uso de laquinimod en alta dosis para el tratamiento de la esclerosis multiple |
| KR20170005434A (ko) | 2014-04-29 | 2017-01-13 | 테바 파마슈티컬 인더스트리즈 리미티드 | 높은 장애 상태를 갖는 재발-완화형 다발성 경화증(rrms) 환자 치료용 라퀴니모드 |
| WO2016059571A1 (en) * | 2014-10-16 | 2016-04-21 | Novartis Ag | Combinations comprising siponimod and laquinimod for the treatment of multiple sclerosis |
| US10091217B2 (en) | 2016-06-21 | 2018-10-02 | Logrhythm, Inc. | Risk based priority processing of data |
| US12097292B2 (en) | 2016-08-28 | 2024-09-24 | Mapi Pharma Ltd. | Process for preparing microparticles containing glatiramer acetate |
| CN109982712A (zh) | 2016-08-31 | 2019-07-05 | Mapi医药公司 | 包含醋酸格拉替雷的储库系统 |
| BR112019017724A2 (pt) * | 2017-03-26 | 2020-03-31 | Mapi Pharma Ltd. | Sistemas depot de glatiramer para tratar formas progressivas de esclerose múltipla |
| EP4178675A4 (en) * | 2020-07-09 | 2024-08-07 | Oklahoma Medical Research Foundation | BIOMARKERS FOR THE IDENTIFICATION OF RELAPSES IN MULTIPLE SCLEROSIS |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE9801474D0 (sv) * | 1998-04-27 | 1998-04-27 | Active Biotech Ab | Quinoline Derivatives |
| US6077851A (en) * | 1998-04-27 | 2000-06-20 | Active Biotech Ab | Quinoline derivatives |
| KR20150065951A (ko) * | 2006-06-12 | 2015-06-15 | 테바 파마슈티컬 인더스트리즈 리미티드 | 안정한 라퀴니모드 제제 |
| PT2187882E (pt) * | 2007-07-11 | 2013-04-17 | Medicinova Inc | Tratamento de uma doença neurodegenerativa progressiva com ibudilast |
| TW201438738A (zh) * | 2008-09-16 | 2014-10-16 | 建南德克公司 | 治療進展型多發性硬化症之方法 |
| AU2009324495B2 (en) * | 2008-12-11 | 2015-12-24 | Biovista, Inc. | Methods for treating multiple sclerosis using tetracyclic pyrazinoindoles |
| EP2442651B1 (en) * | 2009-06-19 | 2015-07-29 | Teva Pharmaceutical Industries Ltd. | Treatment of multiple sclerosis with laquinimod |
| CA2820586A1 (en) * | 2010-12-07 | 2012-06-14 | Teva Pharmaceutical Industries Ltd. | Use of laquinimod for reducing fatigue, improving functional status, and improving quality of life in multiple sclerosis patients |
| SG10201606204TA (en) * | 2011-07-28 | 2016-09-29 | Teva Pharma | Treatment Of Multiple Sclerosis With Combination Of Laquinimod And Interferon-Beta |
| AR090885A1 (es) * | 2012-05-02 | 2014-12-10 | Teva Pharma | Uso de laquinimod en alta dosis para el tratamiento de la esclerosis multiple |
| US20140107154A1 (en) * | 2012-10-12 | 2014-04-17 | Teva Pharmaceutical Industries, Ltd. | Laquinimod for reducing thalamic damage in multiple sclerosis |
| KR20170005434A (ko) * | 2014-04-29 | 2017-01-13 | 테바 파마슈티컬 인더스트리즈 리미티드 | 높은 장애 상태를 갖는 재발-완화형 다발성 경화증(rrms) 환자 치료용 라퀴니모드 |
-
2014
- 2014-02-13 WO PCT/US2014/016278 patent/WO2014127139A1/en not_active Ceased
- 2014-02-13 MX MX2015010296A patent/MX2015010296A/es unknown
- 2014-02-13 CA CA2900503A patent/CA2900503A1/en not_active Abandoned
- 2014-02-13 BR BR112015019564A patent/BR112015019564A2/pt active Search and Examination
- 2014-02-13 HK HK16106269.3A patent/HK1218254A1/zh unknown
- 2014-02-13 JP JP2015558130A patent/JP2016510343A/ja active Pending
- 2014-02-13 US US14/180,173 patent/US20140235670A1/en not_active Abandoned
- 2014-02-13 CN CN201480009035.XA patent/CN105163737A/zh active Pending
- 2014-02-13 HK HK16106220.1A patent/HK1218251A1/zh unknown
- 2014-02-13 AU AU2014216199A patent/AU2014216199A1/en not_active Abandoned
- 2014-02-13 PE PE2015001745A patent/PE20151526A1/es not_active Application Discontinuation
- 2014-02-13 KR KR1020157024953A patent/KR20150119227A/ko not_active Withdrawn
- 2014-02-13 EP EP14751103.4A patent/EP2956137A4/en not_active Withdrawn
- 2014-02-13 SG SG11201505818WA patent/SG11201505818WA/en unknown
- 2014-02-13 EA EA201591507A patent/EA201591507A1/ru unknown
- 2014-02-14 TW TW103104987A patent/TW201442709A/zh unknown
- 2014-02-14 UY UY0001035328A patent/UY35328A/es not_active Application Discontinuation
-
2015
- 2015-07-19 IL IL240014A patent/IL240014A0/en unknown
- 2015-08-05 CL CL2015002181A patent/CL2015002181A1/es unknown
-
2017
- 2017-11-13 US US15/811,139 patent/US20180064702A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CL2015002181A1 (es) | 2016-06-03 |
| WO2014127139A1 (en) | 2014-08-21 |
| AU2014216199A1 (en) | 2015-09-03 |
| EP2956137A1 (en) | 2015-12-23 |
| EP2956137A4 (en) | 2016-08-03 |
| PE20151526A1 (es) | 2015-11-20 |
| EA201591507A1 (ru) | 2015-12-30 |
| KR20150119227A (ko) | 2015-10-23 |
| SG11201505818WA (en) | 2015-08-28 |
| US20140235670A1 (en) | 2014-08-21 |
| IL240014A0 (en) | 2015-09-24 |
| HK1218254A1 (zh) | 2017-02-10 |
| HK1218251A1 (zh) | 2017-02-10 |
| UY35328A (es) | 2014-09-30 |
| TW201442709A (zh) | 2014-11-16 |
| BR112015019564A2 (pt) | 2017-07-18 |
| JP2016510343A (ja) | 2016-04-07 |
| US20180064702A1 (en) | 2018-03-08 |
| CA2900503A1 (en) | 2014-08-21 |
| CN105163737A (zh) | 2015-12-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021000071A (es) | Uso de pridopidina para mejorar la funcion cognitiva y para tratamiento de enfermedad de alzheimer. | |
| HK1218251A1 (zh) | 用拉喹莫德治疗多发性硬化症 | |
| EA033374B9 (ru) | Твердые фармацевтические композиции, содержащие энзалутамид, и способ лечения | |
| PH12016500140A1 (en) | Heterobicycloaryl rorc2 inhibitors and methods of use thereof | |
| PH12012501741A1 (en) | Treatment of lupus arthritis using laquinimod | |
| MX367341B (es) | Tetrahidronaftiridina y compuestos biciclicos relacionados para la inhibicion de la actividad de rorgamma y el tratamiento de enfermedades. | |
| MX2020009780A (es) | Compuestos de inhibidor de autotaxina. | |
| MX337614B (es) | Tratamiento de lupus nefritis usando laquinimod. | |
| PH12012501740A1 (en) | Treatment of rheumatoid arthritis with a combination of laquinimod and methotrexate | |
| EA201691155A1 (ru) | Комбинации ингибиторов гистондеацетилазы и иммуномодулирующих лекарственных средств | |
| MX2019001977A (es) | Metodos y composiciones para tratar esclerosis multiple y trastornos relacionados. | |
| NZ702415A (en) | Methods for treating neutropenia using retinoid agonists | |
| MX2015000398A (es) | Formulaciones de laquinimod sin agente alcalinizante. | |
| MX2016013944A (es) | Laquinimod para el tratamiento de pacientes con esclerosis multiple recidivante-remitente (rrms) con un alto estado de discapacidad. | |
| MX382044B (es) | Oxabicicloheptanos y oxabicicloheptenos para el tratamiento de trastornos depresivos y de estrés. | |
| MX2016005614A (es) | Cuerpos de inclusion para el suministro transdermico de agentes terapeuticos y cosmeticos. | |
| MX2021014120A (es) | Tratamiento de los sintomas asociados a terapia privacion de androgenos. | |
| GB201115977D0 (en) | Neurodevelopmental disorders | |
| MX2016001177A (es) | Tratamiento de esclerosis multiple con la combinacion de laquinimod y flupirtina. | |
| GEP20207145B (en) | Combination of trazodone and gabapentin for the treatmen | |
| MX2016001179A (es) | Tratamiento de esclerosis multiple por induccion de alemtuzumab seguido por terapia de laquinimod. | |
| MX2016003763A (es) | Terapia de combinacion con laquinimod para tratamiento de esclerosis multiple. | |
| PH12020500472A1 (en) | Autotaxin inhibitor compounds | |
| MX2016008214A (es) | Tratamiento de esclerosis multiple con una combinacion de laquinimod y teriflunomida. | |
| AR094809A1 (es) | Tratamiento de formas progresivas de esclerosis múltiple con laquinimod |